ScreenerHero
BCTXBriaCell Therapeutics Corp.
NAS · US · Healthcare · Biotechnology · briacell.com
3.960USD+16.81%Mkt Cap: 34.45M $P/E: —

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
ARGENX SE
$60.19BUSDP/E 39.1
UCB
UCB SA
$45.16BUSDP/E 19.2
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.17BUSDP/E 26.2
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5
ARWR
Arrowhead Pharmaceuticals, Inc.
$12.59BUSD

Key Statistics

Company
Market Cap34.45M $
Enterprise Value10.91M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-30.68M $
Revenue/Share—
Last Price3.960 USD
Fiscal Year EndJul 2025
MR QuarterApr 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.08
PEG—
EV/EBITDA-0.34
EV/Revenue—
P/S—
P/B1.18
EPS (TTM)-0.84
EPS (Forward)-0.39
52W Range
3.38991% of range4.015
52W High4.015 USD
52W Low3.389 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-175.25%
ROA-90.84%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.13M $
CapEx (TTM)456.80K $
FCF Margin—
FCF Yield-58.18%
Net Debt-22.80M $
Net Debt/EBITDA0.71
Balance Sheet
Debt/Equity—
Current Ratio7.07
Quick Ratio6.35
Book Value/Sh3.318 USD
Cash/Share2.621 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 2, 2020
Splits
Last Split1:10
Split DateAug 25, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.8.70M
Float7.86M
Insiders0.51%
Institutions6.39%
Short Interest
Short Ratio2.8d
Short % Float4.70%
Short % Out.4.69%
Shares Short408.29K
Short (prev mo.)380.15K
Technical
SMA 503.402 (+16.4%)
SMA 2005.153 (-23.2%)
Beta1.52
S&P 52W Chg18.16%
Avg Vol (30d)188.81K
Avg Vol (10d)119.37K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—